Nyxoah (NYXH) Projected to Release Earnings on Wednesday

Nyxoah (NASDAQ:NYXH) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Nyxoah to post earnings of ($0.47) per share and revenue of $8.6370 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Nyxoah (NASDAQ:NYXH) last issued its earnings results on Tuesday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.11. Nyxoah had a negative return on equity of 163.73% and a negative net margin of 543.21%.The company had revenue of $7.38 million for the quarter, compared to the consensus estimate of $7.05 million. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nyxoah Price Performance

NASDAQ NYXH opened at $1.40 on Monday. The stock’s 50 day moving average is $1.80 and its 200 day moving average is $3.06. The company has a current ratio of 0.99, a quick ratio of 0.88 and a debt-to-equity ratio of 0.53. Nyxoah has a 12 month low of $1.26 and a 12 month high of $8.59. The stock has a market cap of $54.26 million, a PE ratio of -0.56 and a beta of 1.62.

Institutional Trading of Nyxoah

A number of large investors have recently added to or reduced their stakes in NYXH. Raymond James Financial Inc. boosted its position in shares of Nyxoah by 35.6% during the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after acquiring an additional 3,353 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Nyxoah by 72.4% in the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after purchasing an additional 3,303 shares in the last quarter. Citadel Advisors LLC bought a new stake in Nyxoah in the third quarter worth $98,000. Deutsche Bank AG increased its position in Nyxoah by 40.0% in the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Shay Capital LLC purchased a new stake in Nyxoah during the second quarter valued at $374,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on NYXH shares. Weiss Ratings cut shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Robert W. Baird set a $2.85 target price on shares of Nyxoah in a research report on Thursday, July 9th. Wall Street Zen raised shares of Nyxoah to a “hold” rating in a research note on Saturday. Stifel Nicolaus cut their target price on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, June 17th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $7.00 price target (down from $9.00) on shares of Nyxoah in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.96.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep?disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.